We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Midatech Pharma Plc | LSE:MTPH | London | Ordinary Share | GB00BNGF1L75 | ORD GBP0.02 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.00 | 17.00 | 19.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
21/1/2017 13:23 | Weekly view - the triple share purchase is code for its on the turn. The multi strategy blurb prob means the one that's doing well isn't the one your expecting. Still, he's saying something is selling well. Williams looks LT bowly & poss some inst bites on the volume in anticipation of swinging to profit. Don't how long that is so maybe a longer term play - but CEO & Panmure are dropping hints - poss to inst buyers too who may fancy it here (half IPO) or adjusting their avg entry weight. The tallest volume spikes look like an inst trader trying to nail the btm. The technical damage of the 3 long black bars needs to be repaired at some point (ie go back to the green line). A B/O will confirm. | luckymouse | |
20/1/2017 11:43 | I sold this morning. This announcement was nothing new and the price will drift back if they have no other news. | martinwj | |
20/1/2017 11:21 | n an analyst rating update on Friday shares of Midatech Pharma Plc (LON:MTPH) had their rating reiterated by analysts at Panmure Gordon. The broker said it has now set a ‘Buy’ rating on shares of Midatech Pharma Plc with a price target of 297. | deltrotter | |
20/1/2017 11:20 | Sorry double post. | jamtomorrow2 | |
20/1/2017 11:20 | Double digit sales growth in US based Dara in 2017. Big deal eh! You'd get more than that just on the exchange rate difference. This company has had no good news since the IPO. About time one of their many R&D projects showed some promise. What about the two child patients in the brain cancer trial? Not a mention of their progress. Surely if they were making good progress then every hospital around the world would be requesting a similar trial on their patients. But not a word. Everything is SO slow. | jamtomorrow2 | |
20/1/2017 09:43 | Good news this AM. Looks like the signals from the recent volume uptick in the US were a good pointer to a positive statement. Brokers have a target price well north of this price so suspect this has some way to run. | gwatson56 | |
20/1/2017 08:51 | Yup, the plan was to have their own sales team in place for when their own products are launched. Bigger profits that way. This stock has a long long way to run IMO. | deltrotter | |
20/1/2017 08:38 | Quite like the two part commercialisation strategy with revenues flowing now from the US with a suite of own products in development and hopefully commercialisation in 2018/2019. | hutch_pod | |
20/1/2017 07:30 | That seems to be revenue above forecasts of £8.6m | 18bt | |
18/1/2017 19:05 | It also went up 9% on NASDAQ yesterday. Odd | martinwj | |
18/1/2017 18:56 | Yup, chunky price rise in the US.... | deltrotter | |
18/1/2017 18:55 | Volume over on the Nasdaq has spiked today (as has the price). Gave up on buying any more on the LSE at the official buy price as I was only offered 20 shares. Believe that more were available at a higher price (see someone paid 1.29). | gwatson56 | |
13/1/2017 15:35 | I have high hopes for this stock in 2017. Having said that, I am 60% down on it, so my opinion is probably worthless! Would I buy more now? Yes. | deltrotter | |
13/1/2017 15:31 | There appears to be little on offer as I have not been able to buy any decent size parcel this PM. The best I could get (going through more than one broker on-line) was 500 shares. So if the recent large trades were sells they have been snapped up or the MM's are holding on to them.... Thought that the MMS was 1000 .... still gives me hope for my existing holding.... | gwatson56 | |
11/1/2017 18:11 | 3 interesting delayed trades - 2 million pounds worth - over 3% of the market cap. Must be buys or the price would have plummeted? 16:10:38 11-Jan-2017 120.00 839,388 1,007,265.60 Ordinary Trade - delayed publication 16:10:32 11-Jan-2017 120.00 590,000 708,000.00 Ordinary Trade - delayed publication 16:10:24 11-Jan-2017 120.00 250,000 300,000.00 Ordinary Trade - delayed publication | martinwj | |
03/1/2017 12:41 | This thread now has a more useful header! | solonic | |
15/12/2016 16:40 | And there is an insti picking up 500k.... | deltrotter | |
15/12/2016 10:43 | Yes. At least the cash has been sorted. | hutch_pod | |
14/12/2016 13:37 | I am still confident on this one longer term, but boy has it taken a helluva hit. | deltrotter | |
14/12/2016 13:00 | Suspect we will hear soon re the completion of expansion of Bilbao manufacturing facility for scale-up of sustained release technology. | gwatson56 | |
23/11/2016 08:49 | Ditto. Onwards. | hutch_pod | |
23/11/2016 07:50 | I certainly did. I am hoping for a much improved performance hear in 2017 and their US sales strategy kicks in and we hear news on their trials. | deltrotter | |
22/11/2016 22:29 | Thanks. Hope you took up the offer? | hutch_pod | |
22/11/2016 20:53 | From Proactive - price target 297p and debt-fiance before Christmas?: | deltrotter |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions